Melanoma Clinical Trials in Pittsburgh, Pennsylvania
17 recruitingPittsburgh, Pennsylvania
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+2 more
AstraZeneca60 enrolled11 locationsNCT07115043
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MelanomaThyroid CancerGlioma
Pfizer124 enrolled79 locationsNCT05538130
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Melanoma
Regeneron Pharmaceuticals560 enrolled108 locationsNCT06246916
Recruiting
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Melanoma
John Kirkwood30 enrolled1 locationNCT06599619
Recruiting
Integrated Cancer Repository for Cancer Research
Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled45 locationsNCT02012699
Recruiting
Phase 1Phase 2
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting
Phase 1Phase 2
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
SarcomaMelanomaNSCLC+3 more
ImmVira Pharma Co. Ltd30 enrolled9 locationsNCT04370587
Recruiting
Phase 1Phase 2
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Lung CancerMelanomaMetastatic Lung Cancer+2 more
Obsidian Therapeutics, Inc.52 enrolled9 locationsNCT06060613
Recruiting
Phase 1
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
Melanoma
Yana Najjar20 enrolled1 locationNCT04658303
Recruiting
Evaluation of Hypoxia in Primary Melanoma
Melanoma
Yana Najjar50 enrolled1 locationNCT06831071
Recruiting
Phase 2
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Melanoma
Diwakar Davar26 enrolled1 locationNCT05130177
Recruiting
Early Phase 1
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Melanoma
Yana Najjar25 enrolled1 locationNCT06216938
Recruiting
Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
MelanomaHead and Neck Squamous Cell CarcinomaColo-rectal Cancer
Vyriad, Inc.87 enrolled27 locationsNCT04291105
Recruiting
Phase 2
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 1Phase 2
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
MelanomaAdvanced Solid TumorMetastatic Cancer+3 more
CJ Bioscience, Inc.160 enrolled4 locationsNCT05877430